Eli Lilly offers higher Zepbound weight loss drug doses on LillyDirect

Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the blockbuster injection, such as those with Medicare.

It expands the company’s effort to boost the U.S. supply of Zepbound as demand soars, and to ensure eligible patients are safely accessing the real treatment instead of cheaper compounded versions. 

Eli Lilly is now offering higher doses of Zepbound in single-dose vials through a “self-pay pharmacy” section on its direct-to-consumer website, LillyDirect, which began offering lower doses of the drug in vials in August. Eligible patients diagnosed by a health-care provider with obesity alone or along with obstructive sleep apnea — Zepbound’s newly…